Effectiveness of Lafaxin XR (venlafaxine) in the therapy of recurrent depressive disorders

Authors

  • N.O. Maruta SE “Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine”, Kharkiv, Ukraine
  • V.Yu. Fedchenko SE “Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.7.2020.218248

Keywords:

depressive disorders, recurrent, clinical and psychopathologic manifestations, antidepressive therapy, venlafaxine, Lafaxin XR

Abstract

Background. The increasing prevalence of depressive disorders is an important medical and social problem in current psychiatry. The basic method for depression treatment is pharmacotherapy. The application of effective and safe antidepressants remains a relevant issue in psychiatric practice. The purpose of the study is to investigate the effectiveness and safety of venlafaxine XR in the therapy of patients with depressive disorders. ­Materials and methods. Venlafaxine XR was used in a dose of 75 mg a day with 2-week step titration to the dose of 225 mg a day during 90 days due to the spectrum of neurochemical activity of the medication and involvement of desired noradrenergic effects of the dose mentioned. The peculiarities of the clinical condition and its dynamics were complexly assessed before treatment (day 1), during the treatment period (day 42), and after the therapy (day 90). The persistent monitoring of adverse events and the analysis of their relationship with the studied medication were performed. Results. Venlafaxine XR demonstrated high therapeutic effectiveness and safety. 88.10 % of patients experienced a positive effect with decreasing severity degree of clinical picture (on HDRS) by 50 % and over. Conclusions. Due to both the wide spectrum of antidepressive action and good tolerance venlafaxine XR can be recommended as a drug of choice for the treatment of moderate to severe depressive disorders.

References

Depression. The treatment and Management of depression in adults (updated edition). National Clinical Practice Guideline 90. Режим доступу: www.nice.org.uk/guidance/cg90/evidence/full-guidance-243833293

Терапия антидепрессантами и другие методы лечения депрессивных расстройств. Доклад Рабочей группы CINP на основе обзора доказательных данных. Под ред. В.Н. Краснова. М., 2008. 215 С.

Марута Н.О., Панько Т.В., Федченко В.Ю., Семікіна О.Є. Клініко-психопатологічні прогностичні фактори перебігу первинних депресивних розладів. Психічне здоров’я. 2017. Т. 2, вип. 51. С. 117-119.

Бауэр М., Пфенниг А., Северус Э., Вайбрау П.С., Ангст Ж., Мюллер Х.-Ю. Клинические рекомендации Всемирной федерации обществ биологической психиатрии по биологической терапии униполярных депрессивных расстройств. Часть 1: Острое и продолженное лечение униполярных депрессивных расстройств по состоянию на 2013 год. Современная терапия психических расстройств. 2015. 4. 33-39.

Дробижев М.Ю., Овчинников А.А., Кикта С.В. Механизмы действия антидепрессантов и патогенез психических расстройств. В чем соответствия? Социальная и клиническая психиатрия. 2017. 27 (3). Р. 94-101.

Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates du­ring treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 2001. 178. Р. 234-241.

Vermeiden M.L., Mulder P.G., van den Broek W.W., Bruijn J.A. A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients. J. Psychiatr. Res. 2013. 47. 10. Р. 1337-1342.

Entsuah A.R. et al. Response and remission rates in different subpopulations with major depressive disorder administered Venlafa-xine, selective serotonin reuptake, or placebo. J. Clin. Psychiatry. 2001. 62. 11. Р. 869-877.

Вельтищев Д.Ю. Эффективность венлафаксина (велаксин) при лечении депрессии: результаты современных исследований. Журнал неврологии и психиатрии. 2013. 11. Р. 79-81.

Nemeroff C.B., Entsuah R., Benattia I., Demitrack M., Sloan D.M., Thase M.E. Comprehensive analysis of remission with venlafaxine versus SSRI. Biol. Psychiatr. 2008. 63. Р. 424-434.

Ястребов Д.В. Терапевтически резистентные депрессии в клинике пограничной психиатрии. Журнал неврологии и психиатрии. 2011. 111. 4. С. 47-50.

Мосолов С.Н., Костюкова Е.Г., Городничев А.В., Тимофеев И.В., Ладыженский М.Я., Сердитов О.В. Клиническая эффективность и переносимость препарата венлафаксин (велаксин) при лечении умеренной и тяжелой депрессии. Трудный пациент. 2007. 11. С. 72-78.

Barak Y., Swartz M., Barcuch Y. Venlafaxine or a second SSRI: switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis. Progr. Neuropsychopharmacol. & Biol. Psychiat. 2011. Vol. 35. P. 1744-1747.

Бурчинский С.Г. Венлафаксин в лечении депрессивных расстройств: от фармакологии к фармакотерапии. НейроNews. Здоров’я України. 2015. № 7. С. 30-34.

Smith D., Dempster C., Glanville J. et al. Efficacy and tole-rability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry. 2002. 180. Р. 396-404.

Федченко В.Ю. Фактори прогнозу формування, перебігу та виходу депресивних розладів (клініко-психопатологічні, патопсихологічні та біохімічні підходи). Автореф. дис... д-ра мед. наук. Харків, 2019. 43 с.

Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М.: Медицинское информационное агентство, 2003. 209 с.

Downloads

Published

2020-10-01

Issue

Vol. 16 No. 7 (2020)

Section

To practicing Neurologist

License

Copyright (c) 2020 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.